Myriam Locatelli-Sanchez
Overview
Explore the profile of Myriam Locatelli-Sanchez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meersseman C, Grolleau E, Freymond N, Wallet F, Gilbert T, Locatelli-Sanchez M, et al.
Respir Med Res
. 2023 Sep;
84:101026.
PMID: 37717386
Background: In COVID-19 patients, older age (sixty or older), comorbidities, and frailty are associated with a higher risk for mortality and invasive mechanical ventilation (IMV) failure. It therefore seems appropriate...
2.
Durliat A, Locatelli-Sanchez M, Wallet F, Allaouchiche B
Transpl Infect Dis
. 2022 Nov;
24(6):e13965.
PMID: 36349860
Background: Aspergillosis is a fungal infection with many clinical forms. Invasive aspergillosis is the most widely known severe manifestation, but other forms can need intensive care. Aim: Our purpose is...
3.
Mogenet A, Barlesi F, Besse B, Michiels S, Karimi M, Tran-Dien A, et al.
Lung Cancer
. 2022 May;
169:31-39.
PMID: 35609409
Introduction: Lung cancer remains the most frequent cause of brain metastases (BMs) and is responsible for high morbidity and mortality. Intracranial response to systemic treatments is inconsistent due to several...
4.
Maillet D, Corbaux P, Stelmes J, Dalle S, Locatelli-Sanchez M, Perier-Muzet M, et al.
Eur J Cancer
. 2020 Apr;
132:61-70.
PMID: 32334337
Background: The impact of immune-related adverse events (irAE) on survival outcomes after single-agent immune checkpoint inhibitors (ICIs) remains unclear. We aimed to evaluate the association between irAEs and ICI efficacy...
5.
Corbaux P, Maillet D, Boespflug A, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, et al.
Eur J Cancer
. 2019 Oct;
121:192-201.
PMID: 31590080
Background: Age-related immune dysfunction might impair the efficacy of immune checkpoint inhibitors (ICIs) in older patients. We aimed to evaluate the impact of age on clinical outcomes and tolerance of...
6.
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Do P, Bylicki O, et al.
Lancet Oncol
. 2019 Jan;
20(2):239-253.
PMID: 30660609
Background: There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control has been less than 30% in all previous studies...
7.
Paris C, Do P, Mastroianni B, Dixmier A, Dumont P, Pichon E, et al.
Eur Respir J
. 2017 Oct;
50(4).
PMID: 29074543
Occupational exposure constitutes a common risk factor for lung cancer. We observed molecular alterations in 73% of never-smokers, 35% of men and 8% of women were exposed to at least...
8.
Avrillon V, Locatelli-Sanchez M, Folliet L, Carbonnaux M, Perino E, Fossard G, et al.
Infect Disord Drug Targets
. 2015 Mar;
15(1):57-63.
PMID: 25809625
Introduction: Serum procalcitonin (PCT) is a biomarker used routinely to diagnose infections. Some malignancies are usual false positives for PCT. However, its value and behavior in the setting of lung...
9.
Locatelli-Sanchez M, Couraud S, Arpin D, Riou R, Bringuier P, Souquet P
Lung
. 2013 Jun;
191(5):491-9.
PMID: 23749122
Background: Epidermal growth factor receptor (EGFR)-targeting therapies dramatically modified the prognosis of stage 4 non-small-cell lung cancer. Sensitizing EGFR mutations are the best efficacy factor of these treatments. In 2006,...